Results of a Double-Blind, Randomized, Placebo-Controlled Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Anti-Zika Virus Immunoglobulin
Jane White, Priya Tunga, Deborah M Anderson, Ken Iledan, Tobi Loreth, Geraldine S Parrera, Hugo Astacio, Bojan Drobic, Jason S Richardson, Jane White, Priya Tunga, Deborah M Anderson, Ken Iledan, Tobi Loreth, Geraldine S Parrera, Hugo Astacio, Bojan Drobic, Jason S Richardson
Abstract
Zika virus (ZIKV) is transmitted primarily through infected Aedes aegypti or Aedes albopictus mosquitoes. ZIKV infection during pregnancy was linked to adverse fetal/infant outcomes, including microcephaly, brain anomalies, ocular disorders, intrauterine growth restriction, and other congenital malformations. Human anti-Zika virus immunoglobulin (ZIKV-Ig) is being developed for prophylaxis of ZIKV in at-risk populations, including women of childbearing potential and pregnant women. A phase 1 single-center, double-blind, randomized, placebo-controlled study was conducted to assess the safety and pharmacokinetics (PK) of a single 50.0-mL ZIKV-Ig intravenous dose in healthy adult male or non-pregnant female subjects 18 to 55 years of age. Subjects received either ZIKV-Ig (n = 19) or saline placebo (n = 11). Safety was evaluated based on adverse events (AEs), laboratory test results, physical examinations, and vital signs. Overall, there were 11 subjects (36.7%) with treatment-related AEs including eight subjects (42.1%) in the ZIKV-Ig group and three subjects (27.3%) in the placebo group. Of the AEs considered treatment related, three subjects (15.8%) experienced headache (mild). There were no serious AEs, no deaths, and no discontinuations resulting from AEs. Overall, the safety profile of ZIKV-Ig in this study population of healthy adult subjects appeared to be safe and well tolerated. The results of the pharmacokinetic analysis determined that ZIKV-Ig had a maximum observed concentration of 182.3 U/mL (coefficient of variation, 21.3%), the time at which Cmax occurred of 2.3 hours ± 1.0 (SD), an area under the concentration-time curve0-∞ of 77,224 h × U/mL (coefficient of variation, 17.9%), and a half-life of 28.1 days, which is similar to other human-derived commercial Ig intravenous products.
Trial registration: ClinicalTrials.gov NCT03624946.
Figures
References
- Coelho FC. et al., 2016. Higher incidence of Zika in adult women than adult men in Rio de Janeiro suggests a significant contribution of sexual transmission from men to women. Int J Infect Dis 51: 128–132.
- Hennessey M, Fischer M, Staples JE, 2016. Zika virus spreads to new areas: region of the Americas, May 2015–January 2016. MMWR Morb Mortal Wkly Rep 65: 55–58.
- WHO , 2018. Zika Virus. Geneva, Switzerland: World Health Organization. Available at: . Accessed June 17, 2020.
- WHO , 2019. Countries and Territories with Current or Previous Zika Virus Transmission. Geneva, Switzerland: World Health Organization. Available at: . Accessed June 29, 2020.
- WHO , 2019. World Health Organization Zika Epidemiology Update: July 2019. Geneva, Switzerland: World Health Organization. Available at: . Accessed June 29, 2020.
- Arias A, Torres-Tobar L, Hernandez G, Paipilla D, Palacios E, Torres Y, Duran J, Ugarte US, Ardila-Sierra A, Castellanos G, 2017. Guillain-Barre syndrome in patients with a recent history of Zika in Cucuta, Colombia: a descriptive case series of 19 patients from December 2015 to March 2016. J Crit Care 37: 19–23.
- Dirlikov E. et al., 2016. Guillain-Barre syndrome during ongoing Zika virus transmission: Puerto Rico, January 1–July 31, 2016. MMWR Morb Mortal Wkly Rep 65: 910–914.
- Ritter JM, Martines RB, Zaki SR, 2017. Zika virus: pathology from the pandemic. Arch Pathol Lab Med 141: 49–59.
- Johansson MA, Mier-y-Teran-Romero L, Reefhuis J, Gilboa SM, Hills SL, 2016. Zika and the risk of microcephaly. N Engl J Med 375: 1–4.
- Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT, do Carmo GM, Henriques CM, Coelho GE, Araujo de Franca GV, 2016. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed Zika virus transmission during the first trimester of pregnancy: Brazil, 2015. MMWR Morb Mortal Wkly Rep 65: 242–247.
- Brasil P. et al., 2016. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med 375: 2321–2334.
- Ventura CV. et al., 2016. Risk factors associated with the ophthalmoscopic findings identified in infants with presumed Zika virus congenital infection. JAMA Ophthalmol 134: 912–918.
- Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR, 2016. Zika virus and birth defects: reviewing the evidence for causality. N Engl J Med 374: 1981–1987.
- Moore CA. et al., 2017. Characterizing the pattern of anomalies in congenital Zika syndrome for pediatric clinicians. JAMA Pediatr 171: 288–295.
- Shapiro-Mendoza CK. et al., 2017. Pregnancy outcomes after maternal Zika virus infection during pregnancy: U.S. territories, January 1, 2016–April 25, 2017. MMWR Morb Mortal Wkly Rep 66: 615–621.
- Tabata T, Petitt M, Puerta-Guardo H, Michlmayr D, Wang C, Fang-Hoover J, Harris E, Pereira L, 2016. Zika virus targets different primary human placental cells, suggesting two routes for vertical transmission. Cell Host Microbe 20: 155–166.
- Coyne CB, Lazear HM, 2016. Zika virus: reigniting the TORCH. Nat Rev Microbiol 14: 707–715.
- Aliota MT. et al., 2016. Heterologous protection against Asian Zika virus challenge in Rhesus macaques . PLoS Negl Trop Dis 10: e0005168.
- Chiu CY. et al., 2017. Experimental Zika virus inoculation in a New World monkey model reproduces key features of the human infection. Sci Rep 7: 17126.
- Branche E et al., 2019. Human polyclonal antibodies prevent lethal Zika virus infection in mice. Sci Rep 9: 9857.
- Kurz M, 2008. Developing therapeutic immunoglobulins: European regulatory perspectives and implications. BioDrugs 22: 145–160.
- U.S. Food and Drug Administration , 2020. Immune Globulins. Available at: . Accessed March 4, 2021.
Source: PubMed